-
CUVL share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of CUVL shares has decreased $0.18 since the market last closed. This is a 2.64% drop.
-
Closed at $6.83.
The stock has since dropped $0.25 in after-hours trading.
Key terms
About CUVL
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
-
Market cap: $483.60M
A market capitalization between $300 million and $2 billion places CUVL in the small capitalization category.
Key terms
CUVL Financials
-
CUVL total revenue: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
CUVL net income: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
CUVL earnings per share: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
Key terms
CUVL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CUVL Competitors
-
How competitors are chosen
CUVL's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $483.60M
A market capitalization between $300 million and $2 billion places CUVL in the small capitalization category.
